OpenNashEarnings

Biotechnology · Nasdaq: BIIB

Biogen earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 5 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Biogen's first full quarter with Apellis' eye and kidney drugs pushed growth products to 63% of core pharmaceutical revenue, ahead of December Phase 3 lupus readouts.

Biogen's growth products, led by SPINRAZA high-dose conversions, LEQEMBI and the newly acquired SYFOVRE and EMPAVELI, are now the center of the business while legacy multiple sclerosis drugs decline. LEQEMBI's subcutaneous autoinjector is drawing prescribers who never wrote an Alzheimer's antibody before. Management says Apellis integration is going faster than planned and that the company can now grow even without its pipeline.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$2.8B+10.6% y/yQ3 2026
Q4 2024: $2.5B (worked out from the annual figure)Q4 ’24$2.5BQ1 2025: $2.4BQ1 ’25$2.4BQ2 2025: $2.6BQ2 ’25$2.6BQ3 2025: $2.5BQ3 ’25$2.5BQ4 2025: $2.3B (worked out from the annual figure)Q4 ’25$2.3BQ1 2026: $2.5BQ1 ’26$2.5BQ2 2026: $2.7BQ2 ’26$2.7BQ3 2026: $2.8BQ3 ’26$2.8B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.5B *
Q1 2025$2.4B
Q2 2025$2.6B
Q3 2025$2.5B
Q4 2025$2.3B *
Q1 2026$2.5B
Q2 2026$2.7B
Q3 2026$2.8B
Diluted EPS (GAAP)-$0.14Q3 2026
Q1 2025: $1.64Q1 ’25$1.64Q2 2025: $4.33Q2 ’25$4.33Q3 2025: $3.17Q3 ’25$3.17Q1 2026: $2.15Q1 ’26$2.15Q2 2026: $0.66Q2 ’26$0.66Q3 2026: -$0.14Q3 ’26-$0.14
Data
Q1 2025$1.64
Q2 2025$4.33
Q3 2025$3.17
Q1 2026$2.15
Q2 2026$0.66
Q3 2026-$0.14

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$600.4M−51.0% y/yQ3 2026
Q4 2024: $721.6MQ4 ’24$721.6MQ1 2025: $222.2MQ1 ’25$222.2MQ2 2025: $134.3MQ2 ’25$134.3MQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $468.0MQ4 ’25$468.0MQ1 2026: $594.3MQ1 ’26$594.3MQ2 2026: $408.0MQ2 ’26$408.0MQ3 2026: $600.4MQ3 ’26$600.4M
Data
Q4 2024$721.6M
Q1 2025$222.2M
Q2 2025$134.3M
Q3 2025$1.2B
Q4 2025$468.0M
Q1 2026$594.3M
Q2 2026$408.0M
Q3 2026$600.4M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$2.5Bd$2.4B$2.6B$2.5B$2.3Bd$2.5B$2.7B$2.8B
Net income$266.7Md$240.5M$634.8M$466.5M-$48.9Md$319.5M$97.5M-$20.6M
Diluted EPS—$1.64$4.33$3.17—$2.15$0.66-$0.14
Operating cash flow$760.9Md$259.3M$160.9Md$1.3Bd$511.9Md$645.5M$448.9Md$640.8Md
Capital expenditure$39.3Md$37.1M$26.6Md$46.2Md$43.9Md$51.2M$40.9Md$40.4Md
Free cash flow$721.6M$222.2M$134.3M$1.2B$468.0M$594.3M$408.0M$600.4M
R&D expense$513.3Md$434.1M$399.0M$436.1M$509.4Md$539.0M$529.6M$574.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings